Stock Scorecard
Stock Summary for Outlook Therapeutics Inc (OTLK) - $7.61 as of 9/6/2024 4:07:57 PM EST
Total Score
6 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for OTLK
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for OTLK
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for OTLK
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for OTLK
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Latest News for for OTLK
Financial Details for OTLK
Company Overview |
|
|---|---|
| Ticker | OTLK |
| Company Name | Outlook Therapeutics Inc |
| Country | USA |
| Description | Outlook Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. The company is headquartered in Cranbury, New Jersey. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 6/30/2024 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 7.61 |
| Last Day Price Updated | 9/6/2024 4:07:57 PM EST |
| Last Day Volume | 150,074 |
| Average Daily Volume | 170,475 |
| 52-Week High | 18.00 |
| 52-Week Low | 4.09 |
| Last Price to 52 Week Low | 86.06% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 309.61 |
| Sector PE | 80.12 |
| 5-Year Average PE | -47.48 |
| Free Cash Flow Ratio | 5.64 |
| Industry Free Cash Flow Ratio | 17.61 |
| Sector Free Cash Flow Ratio | 30.42 |
| Current Ratio Most Recent Quarter | 1.07 |
| Total Cash Per Share | 1.35 |
| Book Value Per Share Most Recent Quarter | -3.58 |
| Price to Book Ratio | 10.19 |
| Industry Price to Book Ratio | 10.39 |
| Sector Price to Book Ratio | 22.15 |
| Price to Sales Ratio Twelve Trailing Months | 13.27 |
| Industry Price to Sales Ratio Twelve Trailing Months | 26.85 |
| Sector Price to Sales Ratio Twelve Trailing Months | 6.66 |
Share Statistics |
|
| Total Shares Outstanding | 23,655,600 |
| Market Capitalization | 180,019,116 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Last Dividend Amount | 0.00 |
| Current Dividend Amount | 0.00 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 10.70% |
| Reported EPS 12 Trailing Months | -6.00 |
| Reported EPS Past Year | -8.88 |
| Reported EPS Prior Year | -0.24 |
| Net Income Twelve Trailing Months | -94,048,756 |
| Net Income Past Year | -58,982,668 |
| Net Income Prior Year | -66,052,264 |
| Quarterly Revenue Growth YOY | 658.00% |
| 5-Year Revenue Growth | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 32,024,387 |
| Total Cash Past Year | 23,391,982 |
| Total Cash Prior Year | 17,396,812 |
| Net Cash Position Most Recent Quarter | -407,613 |
| Net Cash Position Past Year | -47,710,018 |
| Long Term Debt Past Year | 71,102,000 |
| Long Term Debt Prior Year | 32,944,548 |
| Total Debt Most Recent Quarter | 32,432,000 |
| Equity to Debt Ratio Past Year | -0.25 |
| Equity to Debt Ratio Most Recent Quarter | 0.00 |
| Total Stockholder Equity Past Year | -14,437,777 |
| Total Stockholder Equity Prior Year | 8,736,571 |
| Total Stockholder Equity Most Recent Quarter | -83,673,488 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -64,553,277 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.73 |
| Free Cash Flow Past Year | 0 |
| Free Cash Flow Prior Year | 0 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.12 |
| MACD Signal | -0.12 |
| 20-Day Bollinger Lower Band | 6.70 |
| 20-Day Bollinger Middle Band | 7.73 |
| 20-Day Bollinger Upper Band | 8.75 |
| Beta | 0.64 |
| RSI | 48.45 |
| 50-Day SMA | 7.95 |
| 150-Day SMA | 20.27 |
| 200-Day SMA | 25.50 |
System |
|
| Modified | 9/7/2024 9:56:49 AM EST |